Replies to post #343579 on Anavex Life Sciences Corp (AVXL)

[falconer66a]

Next few weeks, months, or years?

That [Anavex 3-71 as an approved drug] may be true but in 10 years ? The world will be so different ….

Yes, in 2032 the world will be different. But cellular biology will be unchanged.

You are welcome to presume that it will take ten years before Anavex 3-71 would gain regulatory approval for therapeutic usages. I’ll presume two or three years, based on the successes of the announced Phase I study and use of biomarkers.

“Traders,” equity buyers seeking frequent and consistent buy/sell gains aren’t likely to find AVXL a useful medium for their stock investing perspectives; which are short-term. Until Anavex gets approval to sell one of its drugs somewhere in the world, it will remain a no-revenues, no-product drug development company. Anyone expecting the AVXL share price to begin a steep ascent merely on the basis of Phase I and Phase II clinical results will be disappointed. The “market” always wants to “see” revenues. That’s why it’s a market. Presently, Anavex has not a thing to sell. Holding an AVXL position is speculation, looking out many months or several years.

Clearly, with my several thousand AVXLs I’ve been speculating, for over five years. From the start, I’ve assessed and factored the long time periods it would take for Anavex to achieve profitability. For a number of years I’ve seen 2023 as the first year of profitability. As soon as blarcamesine can be sold to treat Rett syndrome, or Parkinson’s disease dementia, or, especially, Alzheimer’s, Anavex Life Sciences Corp will be destined to become a major, global pharmaceutical.

If you want consistent equity investment gains do the homework on an ETF, Exchange Traded Fund. Just buy a position and sit back and watch it grow each day (or decline for certain periods). No knowledge of cellular biology is required or useful. No anxious anticipation of “corporate announcements.”

The continued postings lamenting low or declining AVXL prices are tedious. Only stock traders care. And most know better, don’t mess with no-rev start ups like Anavex. Like most, with a chuckle (or smirk), I read those naysaying postings. But, I don’t care. The only thing that will count is FDA (or other) approval to sell and use blarcamesine. Everything continues to point toward that. With today’s Anavex 3-71 announcement, that drug, too, is headed for approval.

But not in the next few days, weeks, or months. Most probably in 2023 and 2024. After that....? Use your spreadsheet to factor the share price gains. Short term or long term. Two different Anavex viewpoints. Like others, I’m on the high ground, looking beyond the day to day froth and murk of the short-termers. Let’s all check back in five years.